This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pfizer, AmSurg: New Targets, Estimates

Stocks in this article: AMSGADSHSIMAXPCLNPFEPIRSTX

Also see: Expedia, Citigroup, Target: New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Alliance Data (ADS) target boosted at RBC. Shares of ADS now seen reaching $96, according to RBC. Company should reach it's near-term earnings targets. Outperform rating.

AmSurg Corp (AMSG) price target boosted at Citi to $32.50 from $24. Bullish on acquisition of Dallas based National Surgical Care, Citigroup said. Maintain Buy rating.

Constellation (STZ) estimates, target upped at UBS. STZ estimates were boosted through 2013, UBS said. Company is realizing higher shipments. Buy rating and new $25 price target.

Healthspring (HS) estimates reduced at Goldman through 2013, Goldman Sachs said. Company is realizing a lower Medicare reimbursement. Neutral rating and $46 price target.

Imax (IMAX) target raised at Piper. Shares of IMAX now seen reaching $37. Company is expanding its reach across the globe. Overweight rating.

JC Penney (JCP) numbers upped at Piper. JCP estimates were boosted through 2012, Piper Jaffray said. Company is realizing higher sales. Neutral rating and new $32 price target.

Limited Brands (LTD) target boosted at Morgan Stanley. Shares of LTD now seen reaching $41, according to Morgan Stanley. Company is posting double-digit sales growth. Overweight rating.

Priceline.com (PCLN) estimates, target raised at Goldman. Shares of PCLN now seen reaching $600, according to Goldman Sachs. Estimates also increased, given expected growth in Europe. Buy rating.

Pepsico (PEP) estimates lowered at Goldman through 2012, Goldman Sachs said. Company is spending more on domestic marketing. Buy rating and $77 price target.

Pfizer (PFE) price target raised at Credit Suisse to $23 from $21. Value exists in the case of a Pfizer Animal Health spin-off, Credit Suisse said. Maintain Outperform rating.

Pier 1 Imports (PIR) price target higher at Credit Suisse. PIR shares now seen reaching $13, up from $11. Strong comps reinforce solid long-term growth, Credit Suisse said. Maintain Neutral rating.

Seagate Technology (STX) numbers increased at Goldman through 2013, Goldman Sachs said. Company is realizing higher margins. Neutral rating and new $16 price target.

Target price target reduced at Goldman to $60, according to Goldman Sachs. Cinoany is seeing weaker sales. Buy rating.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs